Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus

Clinical Immunology

Volumn 154, Issue 1, 2014, Pages 1-12

  Martin, Jérôme C ^a,b,c   Baeten, Dominique L ^d   Josien, Régis ^a,b,c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

IL 17; SLE; Th17

Indexed keywords

INTERLEUKIN 17;

ANKYLOSING SPONDYLITIS; AUTOINFLAMMATORY DISEASE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL;

IL-17; SLE; TH17;

HUMANS; INTERLEUKIN-17; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; TH17 CELLS;

EID: 84903782016     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.05.004     Document Type: Review

References (142)

1. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
2. Pons-Estel G.J., Alarcón G.S., Scofield L., Reinlib L., Cooper G.S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010, 39:257-268.
3. Liu Z., Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat. Med. 2012, 18:871-882.
4. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
5. Murphy G., Lisnevskaia L., Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 2013, 382:809-818.
6. Navarra S.V., Guzmán R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
7. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3918-3930.
8. Yao Y., Richman L., Higgs B.W., Morehouse C.A., de los Reyes M., Brohawn P., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1785-1796.
9. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010, 62:542-552.
10. Rouvier E., Luciani M.F., Mattéi M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993, 150:5445-5456.
11. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17Family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25:821-852.
12. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9:556-567.
13. Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci. Signal. 2009, 2:ra63.
14. Hartupee J., Liu C., Novotny M., Li X., Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 2007, 179:4135-4141.
15. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin. Sci. (Lond.) 2012, 122:487-511.
16. Bulek K., Liu C., Swaidani S., Wang L., Page R.C., Gulen M.F., et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat. Immunol. 2011, 12:844-852.
17. Sun D., Novotny M., Bulek K., Liu C., Li X., Hamilton T. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 2011, 12:853-860.
18. Weaver C.T., Elson C.O., Fouser L.A., Kolls J.K. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu. Rev. Pathol. 2013, 8:477-512.
19. Puel A., Döffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 2010, 207:291-297.
20. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.
21. Liu L., Okada S., Kong X.-F., Kreins A.Y., Cypowyj S., Abhyankar A., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011, 208:1635-1648.
22. Boisson B., Wang C., Pedergnana V., Wu L., Cypowyj S., Rybojad M., et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 2013, 39:676-686.
23. Ma C.S., Chew G.Y.J., Simpson N., Priyadarshi A., Wong M., Grimbacher B., et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 2008, 205:1551-1557.
24. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996, 183:2593-2603.
25. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
26. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.-H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
27. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
28. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
29. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
30. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
31. Volpe E., Servant N., Zollinger R., Bogiatzi S.I., Hupé P., Barillot E., et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 2008, 9:650-657.
32. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10:314-324.
33. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
34. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
35. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198:1951-1957.
36. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
37. Esplugues E., Huber S., Gagliani N., Hauser A.E., Town T., Wan Y.Y., et al. Control of TH17 cells occurs in the small intestine. Nature 2011, 475:514-518.
38. Zielinski C.E., Mele F., Aschenbrenner D., Jarrossay D., Ronchi F., Gattorno M., et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012, 484:514-518.
39. El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12:568-575.
40. Codarri L., Gyülvészi G., Tosevski V., Hesske L., Fontana A., Magnenat L., et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
41. Lee Y., Awasthi A., Yosef N., Quintana F.J., Xiao S., Peters A., et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13:991-999.
42. Hirota K., Duarte J.H., Veldhoen M., Hornsby E., Li Y., Cua D.J., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 2011, 12:255-263.
43. Liang S.C., Tan X.-Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 2006, 203:2271-2279.
44. Wolk K., Haugen H.S., Xu W., Witte E., Waggie K., Anderson M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. 2009, 87:523-536.
45. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 2010, 207:1293-1305.
46. Peters A., Lee Y., Kuchroo V.K. The many faces of Th17 cells. Curr. Opin. Immunol. 2011, 23:702-706.
47. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 2010, 10:479-489.
48. Sutton C.E., Mielke L.A., Mills K.H.G. IL-17-producing γδ T cells and innate lymphoid cells. Eur. J. Immunol. 2012, 42:2221-2231.
49. Kenna T.J., Brown M.A. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat. Rev. Rheumatol. 2013, 9:375-379.
50. Sherlock J.P., Joyce-Shaikh B., Turner S.P., Chao C.-C., Sathe M., Grein J., et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8- entheseal resident T cells. Nat. Med. 2012, 18:1069-1076.
51. Appel H., Maier R., Wu P., Scheer R., Hempfing A., Kayser R., et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res. Ther. 2011, 13:R95.
52. Noordenbos T., Yeremenko N., Gofita I., van de Sande M., Tak P.P., Caňete J.D., et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012, 64:99-109.
53. Kenna T.J., Davidson S.I., Duan R., Bradbury L.A., McFarlane J., Smith M., et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012, 64:1420-1429.
54. Sánchez E., Rueda B., Callejas J.L., Sabio J.M., Ortego-Centeno N., Jimenez-Alonso J., et al. Analysis of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus. Tissue Antigens 2007, 70:233-237.
55. Kim H.-S., Kim I., Kim J.O., Bae J.S., Shin H.D., Bae S.-C. No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. Rheumatol. Int. 2009, 30:33-38.
56. Sestak A.L., Fürnrohr B.G., Harley J.B., Merrill J.T., Namjou B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i37-i43.
57. Yu B., Guan M., Peng Y., Shao Y., Zhang C., Yue X., et al. Copy number variations of interleukin-17F, interleukin-21, and interleukin-22 are associated with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3487-3492.
58. Wong C.K., Lit L.C.W., Tam L.S., Li E.K.M., Wong P.T.Y., Lam C.W.K. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 2008, 127:385-393.
59. Cheng F., Guo Z., Xu H., Yan D., Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2009, 68:604-606.
60. Chen X.Q., Yu Y.C., Deng H.H., Sun J.Z., Dai Z., Wu Y.W., et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J. Clin. Immunol. 2010, 30:221-225.
61. Zhao X.-F., Pan H.-F., Yuan H., Zhang W.-H., Li X.-P., Wang G.-H., et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol. Biol. Rep. 2010, 37:81-85.
62. Tanasescu C., Balanescu E., Balanescu P., Olteanu R., Badea C., Grancea C., et al. IL-17 in cutaneous lupus erythematosus. Eur. J. Intern. Med. 2010, 21:202-207.
63. Vincent F.B., Northcott M., Hoi A., Mackay F., Morand E.F. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res. Ther. 2013, 15:R97.
64. Yang X., Wang H., Zhao X., Wang L., Lv Q., Wang Q. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J. Clin. Immunol. 2013, 33:767-774.
65. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000, 43:2455-2463.
66. Crispín J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008, 181:8761-8766.
67. Yang J., Chu Y., Yang X., Gao D., Zhu L., Yang X., et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1472-1483.
68. Oh S.H., Roh H.J., Kwon J.E., Lee S.H., Kim J.Y., Choi H.J., et al. Expression of interleukin-17 is correlated with interferon-α expression in cutaneous lesions of lupus erythematosus. Clin. Exp. Dermatol. 2011, 36:512-520.
69. Shah K., Lee W.-W., Lee S.-H., Kim S.H., Kang S.W., Craft J., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12:R53.
70. Dolff S., Bijl M., Huitema M.G., Limburg P.C., Kallenberg C.G.M., Abdulahad W.H. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin. Immunol. 2011, 141:197-204.
71. Xing Q., Wang B., Su H., Cui J., Li J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol. Int. 2012, 32:949-958.
72. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 2007, 8:639-646.
73. Pan H.-F., Zhao X.-F., Yuan H., Zhang W.-H., Li X.-P., Wang G.-H., et al. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin. Chim. Acta Int. J. Clin. Chem. 2009, 401:179-180.
74. Zhao L., Jiang Z., Jiang Y., Ma N., Wang K., Zhang Y., et al. IL-22+CD4+ T-cells in patients with active systemic lupus erythematosus. Exp. Biol. Med. (Maywood) 2013, 238:193-199.
75. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
76. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
77. Huber S., Gagliani N., Zenewicz L.A., Huber F.J., Bosurgi L., Hu B., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
78. Martin J.C., Bériou G., Heslan M., Chauvin C., Utriainen L., Aumeunier A., et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol. 2013, 7:101-113.
79. Shivakumar S., Tsokos G.C., Datta S.K. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 1989, 143:103-112.
80. Crispín J.C., Tsokos G.C. Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J. Immunol. 2009, 183:4675-4681.
81. Solomou E.E., Juang Y.T., Gourley M.F., Kammer G.M., Tsokos G.C. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 2001, 166:4216-4222.
82. Kyttaris V.C., Wang Y., Juang Y.T., Weinstein A., Tsokos G.C. CAMP response element modulator a expression in patients with systemic lupus erythematosus. Lupus 2006, 15:840-844.
83. Hedrich C.M., Rauen T., Crispin J.C., Koga T., Ioannidis C., Zajdel M., et al. cAMP-responsive element modulator α (CREMα) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease. J. Biol. Chem. 2013, 288:31880-31887.
84. Hedrich C.M., Crispin J.C., Rauen T., Ioannidis C., Koga T., Rodriguez Rodriguez N., et al. cAMP responsive element modulator (CREM)α mediates chromatin remodeling of CD8 during the generation of CD3+CD4-CD8- T cells. J. Biol. Chem. 2013, 288:1880-1887.
85. Wang Y., Ito S., Chino Y., Goto D., Matsumoto I., Murata H., et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin. Exp. Immunol. 2010, 159:1-10.
86. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
87. Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 2011, 187:538-552.
88. Linker-Israeli M., Deans R.J., Wallace D.J., Prehn J., Ozeri-Chen T., Klinenberg J.R. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 1991, 147:117-123.
89. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 2005, 202:1131-1139.
90. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
91. Yu C.-F., Peng W.-M., Oldenburg J., Hoch J., Bieber T., Limmer A., et al. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J. Immunol. 2010, 184:1159-1167.
92. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011, 3:73ra20.
93. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011, 3:73ra19.
94. Segura E., Touzot M., Bohineust A., Cappuccio A., Chiocchia G., Hosmalin A., et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013, 38:336-348.
95. Persson E.K., Uronen-Hansson H., Semmrich M., Rivollier A., Hägerbrand K., Marsal J., et al. IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity 2013, 38:958-969.
96. Schlitzer A., McGovern N., Teo P., Zelante T., Atarashi K., Low D., et al. IRF4 transcription factor-dependent CD11b(+) dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013, 38:970-983.
97. Taylor P.R., Roy S., Leal S.M., Sun Y., Howell S.J., Cobb B.A., et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 2013, 15:143-151.
98. Smith S., Gabhann J.N., Higgs R., Stacey K., Wahren-Herlenius M., Espinosa A., et al. Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus. Arthritis Rheum. 2012, 64:1601-1609.
99. Shin M.S., Kang Y., Lee N., Wahl E.R., Kim S.H., Kang K.S., et al. Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J. Immunol. 2013, 190:1407-1415.
100. Cros J., Cagnard N., Woollard K., Patey N., Zhang S.-Y., Senechal B., et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33:375-386.
101. Hänsel A., Günther C., Baran W., Bidier M., Lorenz H.-M., Schmitz M., et al. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J. Autoimmun. 2013, 40:1-8.
102. Hänsel A., Günther C., Ingwersen J., Starke J., Schmitz M., Bachmann M., et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J. Allergy Clin. Immunol. 2011, 127:787-794. (e1-9).
103. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 1982, 69:1388-1392.
104. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
105. Hedrich C.M., Crispin J.C., Rauen T., Ioannidis C., Apostolidis S.A., Lo M.S., et al. cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16606-16611.
106. Rauen T., Hedrich C.M., Juang Y.-T., Tenbrock K., Tsokos G.C. cAMP-responsive element modulator (CREM)α protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem. 2011, 286:43437-43446.
107. Moulton V.R., Tsokos G.C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res. Ther. 2011, 13:207.
108. Chatterjee M., Rauen T., Kis-Toth K., Kyttaris V.C., Hedrich C.M., Terhorst C., et al. Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. J. Immunol. 2012, 188:1206-1212.
109. Isgro J., Gupta S., Jacek E., Pavri T., Duculan R., Kim M., et al. Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum. 2013, 65:1592-1602.
110. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009, 183:3160-3169.
111. Kyttaris V.C., Zhang Z., Kuchroo V.K., Oukka M., Tsokos G.C. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. 2010, 184:4605-4609.
112. Kido M., Takeuchi S., Sugiyama N., Esaki H., Nakashima H., Yoshida H., et al. T cell-specific overexpression of interleukin-27 receptor α subunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice. Br. J. Dermatol. 2011, 164:1214-1220.
113. Hsu H.-C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 2008, 9:166-175.
114. Espinosa A., Dardalhon V., Brauner S., Ambrosi A., Higgs R., Quintana F.J., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J. Exp. Med. 2009, 206:1661-1671.
115. Pisitkun P., Ha H.-L., Wang H., Claudio E., Tivy C.C., Zhou H., et al. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012, 37:1104-1115.
116. Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35:986-996.
117. Hirota K., Turner J.-E., Villa M., Duarte J.H., Demengeot J., Steinmetz O.M., et al. Plasticity of Th17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 2013, 14:372-379.
118. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 2006, 203:2577-2587.
119. Rizzo H.L., Kagami S., Phillips K.G., Kurtz S.E., Jacques S.L., Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J. Immunol. 2011, 186:1495-1502.
120. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
121. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
122. McInnes I.B., Kavanaugh A., Gottlieb A.B., Puig L., Rahman P., Ritchlin C., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382:780-789.
123. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 2014, 73:990-999.
124. Poddubnyy D., Hermann K.-G.A., Callhoff J., Listing J., Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 2014, 73:817-823.
125. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
126. Sandborn W.J., Gasink C., Gao L.-L., Blank M.A., Johanns J., Guzzo C., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012, 367:1519-1528.
127. De Souza A., Ali-Shaw T., Strober B.E., Franks A.G. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch. Dermatol. 2011, 147:896-898.
128. Winchester D., Duffin K.C., Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus 2012, 21:1007-1010.
129. Dahl C., Johansen C., Kragballe K., Olesen A.B. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm. Venereol. 2013, 93:368-369.
130. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2:52ra72.
131. Papp K.A., Langley R.G., Sigurgeirsson B., Abe M., Baker D.R., Konno P., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br. J. Dermatol. 2013, 168:412-421.
132. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366:1190-1199.
133. Papp K.A., Leonardi C., Menter A., Ortonne J.-P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 2012, 366:1181-1189.
134. Baeten D., Baraliakos X., Braun J., Sieper J., Emery P., van der Heijde D., et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013, 382:1705-1713.
135. McInnes I.B., Sieper J., Braun J., Emery P., van der Heijde D., Isaacs J.D., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 2014, 73:349-356.
136. Baeten D.L.P., Kuchroo V.K. How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat. Med. 2013, 19:824-825.
137. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Mazurov V., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. 2013, 72:863-869.
138. Genovese M.C., Greenwald M., Cho C.-S., Berman A., Jin L., Cameron G.S., et al. Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-naïve or TNF-IR patients with rheumatoid arthritis. Arthritis Rheumatol. 2014, (in press).
139. Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D.R., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
140. Voulgarelis M., Tzioufas A.G. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat. Rev. Rheumatol. 2010, 6:529-537.
141. Sumida T., Tsuboi H., Iizuka M., Hirota T., Asashima H., Matsumoto I. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review. J. Autoimmun. 2014, 51C:44-50.
142. Nguyen C.Q., Yin H., Lee B.H., Carcamo W.C., Chiorini J.A., Peck A.B. Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res. Ther. 2010, 12:R220.